JAZZ
Price
$141.67
Change
+$4.96 (+3.63%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
8.3B
110 days until earnings call
Intraday BUY SELL Signals
TECH
Price
$60.76
Change
-$0.64 (-1.04%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
9.57B
82 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

JAZZ vs TECH

Header iconJAZZ vs TECH Comparison
Open Charts JAZZ vs TECHBanner chart's image
Jazz Pharmaceuticals
Price$141.67
Change+$4.96 (+3.63%)
Volume$54.18K
Capitalization8.3B
Bio-Techne
Price$60.76
Change-$0.64 (-1.04%)
Volume$66.79K
Capitalization9.57B
JAZZ vs TECH Comparison Chart in %
JAZZ
Daily Signal:
Gain/Loss:
TECH
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
JAZZ vs. TECH commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAZZ is a StrongBuy and TECH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (JAZZ: $136.71 vs. TECH: $61.40)
Brand notoriety: JAZZ and TECH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JAZZ: 136% vs. TECH: 109%
Market capitalization -- JAZZ: $8.3B vs. TECH: $9.57B
JAZZ [@Biotechnology] is valued at $8.3B. TECH’s [@Biotechnology] market capitalization is $9.57B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JAZZ’s FA Score shows that 0 FA rating(s) are green whileTECH’s FA Score has 1 green FA rating(s).

  • JAZZ’s FA Score: 0 green, 5 red.
  • TECH’s FA Score: 1 green, 4 red.
According to our system of comparison, both JAZZ and TECH are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JAZZ’s TA Score shows that 6 TA indicator(s) are bullish while TECH’s TA Score has 6 bullish TA indicator(s).

  • JAZZ’s TA Score: 6 bullish, 2 bearish.
  • TECH’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, JAZZ is a better buy in the short-term than TECH.

Price Growth

JAZZ (@Biotechnology) experienced а -0.37% price change this week, while TECH (@Biotechnology) price change was +2.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

JAZZ is expected to report earnings on Mar 03, 2026.

TECH is expected to report earnings on Feb 03, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TECH($9.57B) has a higher market cap than JAZZ($8.31B). TECH has higher P/E ratio than JAZZ: TECH (125.31) vs JAZZ (15.38). JAZZ YTD gains are higher at: 11.011 vs. TECH (-14.389). JAZZ has higher annual earnings (EBITDA): 372M vs. TECH (217M). JAZZ has more cash in the bank: 1.67B vs. TECH (162M). TECH has less debt than JAZZ: TECH (444M) vs JAZZ (5.43B). JAZZ has higher revenues than TECH: JAZZ (4.09B) vs TECH (1.22B).
JAZZTECHJAZZ / TECH
Capitalization8.31B9.57B87%
EBITDA372M217M171%
Gain YTD11.011-14.389-77%
P/E Ratio15.38125.3112%
Revenue4.09B1.22B335%
Total Cash1.67B162M1,031%
Total Debt5.43B444M1,224%
FUNDAMENTALS RATINGS
JAZZ vs TECH: Fundamental Ratings
JAZZ
TECH
OUTLOOK RATING
1..100
6968
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
86
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9386
PRICE GROWTH RATING
1..100
4651
P/E GROWTH RATING
1..100
6611
SEASONALITY SCORE
1..100
5031

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JAZZ's Valuation (73) in the Pharmaceuticals Other industry is in the same range as TECH (86) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to TECH’s over the last 12 months.

JAZZ's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as TECH (100) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to TECH’s over the last 12 months.

TECH's SMR Rating (86) in the Biotechnology industry is in the same range as JAZZ (93) in the Pharmaceuticals Other industry. This means that TECH’s stock grew similarly to JAZZ’s over the last 12 months.

JAZZ's Price Growth Rating (46) in the Pharmaceuticals Other industry is in the same range as TECH (51) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to TECH’s over the last 12 months.

TECH's P/E Growth Rating (11) in the Biotechnology industry is somewhat better than the same rating for JAZZ (66) in the Pharmaceuticals Other industry. This means that TECH’s stock grew somewhat faster than JAZZ’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
JAZZTECH
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
62%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
71%
MACD
ODDS (%)
Bearish Trend 2 days ago
50%
Bearish Trend 2 days ago
68%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
55%
Bullish Trend 2 days ago
70%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
67%
Advances
ODDS (%)
Bullish Trend 3 days ago
60%
Bullish Trend 2 days ago
73%
Declines
ODDS (%)
Bearish Trend 7 days ago
57%
Bearish Trend 7 days ago
72%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
60%
Aroon
ODDS (%)
Bullish Trend 2 days ago
53%
Bullish Trend 2 days ago
62%
View a ticker or compare two or three
Interact to see
Advertisement
JAZZ
Daily Signal:
Gain/Loss:
TECH
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
KBA30.460.17
+0.56%
KraneShares Bosera MSCIChinaA50CntIdETF
RSSE21.180.05
+0.23%
FT Vest U.S. Eq Eql Wght Buffr ETF - Sep
APED12.81N/A
N/A
Stkd 100% Mstr & 100% Coin ETF
TAFI25.25-0.02
-0.10%
AB Tax-Aware Short Duration ETF
XOMO11.86-0.09
-0.75%
YieldMax XOM Option Income Strategy ETF

JAZZ and

Correlation & Price change

A.I.dvisor indicates that over the last year, JAZZ has been loosely correlated with BMRN. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if JAZZ jumps, then BMRN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAZZ
1D Price
Change %
JAZZ100%
-0.29%
BMRN - JAZZ
50%
Loosely correlated
+0.71%
AMLX - JAZZ
43%
Loosely correlated
-2.76%
TECH - JAZZ
42%
Loosely correlated
+3.75%
IRON - JAZZ
40%
Loosely correlated
-0.06%
FTRE - JAZZ
39%
Loosely correlated
-3.82%
More

TECH and

Correlation & Price change

A.I.dvisor indicates that over the last year, TECH has been loosely correlated with AXON. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if TECH jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TECH
1D Price
Change %
TECH100%
+3.75%
AXON - TECH
61%
Loosely correlated
-0.47%
BMRN - TECH
51%
Loosely correlated
+0.71%
MRNA - TECH
45%
Loosely correlated
+1.14%
MRVI - TECH
44%
Loosely correlated
N/A
ARRY - TECH
44%
Loosely correlated
-8.69%
More